Although many cancer types did not show a significant survival ratio, ACE2 was significant in brain cancer (HR 0.44; p 0.003), breast cancer (HR 1.23; p 0.002), lung cancer (HR 0.7; p 0.009), ovarian cancer (HR 0.63; p 0.048) and renal cell carcinoma (HR 0.17; p 0.021). Here, ACE2 is linked to ovarian carcinoma.